Fig. 5: NCT reduced inflammatory markers in mouse livers and human primary hepatocytes. | Cell Death & Disease

Fig. 5: NCT reduced inflammatory markers in mouse livers and human primary hepatocytes.

From: Long-term oral administration of an HNF4α agonist prevents weight gain and hepatic steatosis by promoting increased mitochondrial mass and function

Fig. 5

A–C qPCR analysis in mouse liver of IL-6, TNFα, and IL-1β mRNA levels normalized to 18s rRNA (NC, N = 3, HFD and HFD + NCT, N = 12). D ELISA analysis for IL-6 secreted into the medium of human primary hepatocytes cultured in palmitate and DMSO (vehicle control) or different concentrations of NCT (N = 3). E, F qPCR analysis of IL-6 and TNFα mRNA level in primary human hepatocytes. Normalization was to 18s rRNA (N = 3). G, H Nitric oxide (NO) analysis in in vivo and in vitro. NO expression normalized to liver weight in vivo (NC, N = 3; HFD and HFD + NCT, N = 4) and normalized to protein in T6PNE cells in vitro (N = 3). I Alanine aminotransferase (ALT) level in blood was reduced in HFD + NCT mice compared to HFD mice (NC, N = 3; HFD, N = 12; HFD + NCT, N = 9). Dots indicate individual mouse or human donors. Values represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (HFD vs. NC or HFD + NCT, 0 μM vs. each concentration of NCT in human hepatocyte and T6PNE cells). NS non-significant.

Back to article page